secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2023-09-07T23:59:59+00:00
Accession:  0000950170-23-046889
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics President & Chairman Novak to resign Sept 15; CEO Kulkarni to become Chairman
--------------------------------------------------------------------------------

- Rodger Novak resigns as President and Chairman, effective September 15, 2023; no dispute or disagreement cited.
- Samarth Kulkarni, Ph.D., CEO, appointed Chairman of the Board effective same date; will continue as CEO.
- Novak co-founded CRISPR nearly 10 years ago, was instrumental in key collaborations and exa-cel development.
- Kulkarni's compensation arrangement remains unchanged; Board thanks Novak for his leadership.
- CRISPR's exa-cel for sickle cell disease and beta thalassemia is under regulatory review for potential first CRISPR-based medicine approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023046889/0000950170-23-046889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023046889/crsp-20230904.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-046889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer